Shield Therapeutics takes bold approach in the US

0
12
  • Shield Therapeutics building a solid brand base says new Proactive research
  • Shield Therapeutics’ present drive for US launch success of iron deficiency product Accrufer
Shield Therapeutics PLC -

Quick facts: Shield Therapeutics PLC

Follow

View company profile

Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company delivering innovative speciality pharmaceuticals to address significant unmet needs in the treatment of iron deficiency and hyperphosphatemia.

The company’s lead product Feraccru(R)/Accrufer(R) is a novel, stable, non-salt based oral therapy and is approved in the United States, European Union, UK and Switzerland for the treatment of iron deficiency with or without anaemia in adults.

In Europe the product is marketed as Feraccru(R) with commercialisation led by Norgine BV. In the USA the product is marketed as Accrufer(R).

Shield also has an exclusive licence agreement with ASK Pharm who will lead development and commercialisation in China, Hong Kong, Macau and Taiwan.

16 Nov 2021

Proactive Research has published a new note on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) ahead of the launch of iron deficiency drug Accrufer in the US.

In Europe, the drug is branded as Ferracru and marketed by partner Norgine.

Accrufer is an effective oral product to treat iron deficiency (anaemia), says Proactive analyst John Savin.

In addition, Accrufer is positioned against ineffective, if cheap, generic oral iron products that have significant gastrointestinal side effects.

Read more

27 Sep 2021

Shield Therapeutics PLC (LSE:STX, FRA:1JS) said Jose A. Menoyo, M.D., is joining its senior executive team as vice president and chief medical officer with immediate effect, in a move that is expected to help the launch of its iron deficiency treatment Accrufer in the US.

Dr. Menoyo most recently served as head of US Medical Affairs at rare disease specialist Alexion Pharmaceuticals, Inc., which was acquired by AstraZeneca PLC (LSE:AZN) in July this year. In this role, Menoyo led the Medical Affairs and Health Outcomes and Research teams that supported several launches in the rare disease area.

Read more

17 Aug 2021

Shield Therapeutics PLC (LSE:STX, FRA:1JS) (LSE:STX) said in its half-year results that the focus in the second half will be on the roll-out of its iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

Read more

17 Aug 2021

Shield Therapeutics PLC (LSE:STX, FRA:1JS) (LSE:STX) new CEO Greg Madison talks to Proactive London about his strategy for the company and focus on driving the iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

During the second quarter of 2021, the company built up a sales force and started to contact key prescribers. Due to the ongoing impact of the COVID pandemic and the emergence of the delta variant in the US, face-to-face contact with clinicians has been limited in the initial phase of launch but discussions are taking place with payers regarding formulary placement of Accrufer and will continue over the next several months.

16 Nov 2021

Shield Therapeutics is a UK-based company actively and directly marketing its approved product, Accrufer, in the US. In Europe, it is branded as Ferracru and marketed by partner Norgine. Accrufer is an effective oral product to treat iron deficiency (anaemia). Accrufer is positioned against ineffective, if cheap, generic oral iron products that have significant gastrointestinal side effects. This makes Shield one of the few UK companies to both achieve full FDA approval and to gain the maximum US-market profit from its R&D investments. This note looks at the current position of Accrufer ahead of potential trading updates and FY21 results over the next few months.

Read full report



Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics: building the brand base as it progresses with Accrufer…

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the company has an advantage as one of the few UK-based firms marketing an approved product into the US market.

Savin telling Proactive that Accrufer, a…

8 hours, 10 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here